Mitsubishi Tanabe hit with manufacturing suspensions over albumin problems
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has slapped a nearly one-month suspension on parts of Mitsubishi Tanabe Pharma's (MTP) business, in relation to quality and data issues which led to the domestic recall of a recombinant human serum albumin product around a year ago.